EarningsQ3 2026 Earnings Report
MX:A Q3 2026 EPS Results
Actual EPS$27.91
Consensus EPS$25.64
Beat/MissBeat by +$2.27
One Year Ago EPS$23.60
MX:A Q3 2026 Revenue Results
Actual Revenue$32.36B
Expected Revenue$31.73B
Beat/MissBeat by +$628.68M
YoY Revenue Growth+8.06%
Earnings Announcement Details
QuarterQ3 2026
Date08/26/2026
TimeAfter Close
Conference CallWednesday, August 26, 2026
MX:A Upcoming Earnings
Agilent's next earnings date is estimated for November 30, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:A Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.Company Guidance
Revenue Beat and Organic Growth
Reported Q3 revenue of $1.88B, core (organic constant currency) growth of 7.3% year-over-year, and reported growth of 8.1%. Revenue exceeded the high end of guidance by ~140 basis points.
Strong Margin and EPS Performance
Non-GAAP operating margin of 27.2% excluding tariff refunds (28.3% including ~$20M tariff refund). Operating margin expanded ~210 bps year-over-year on an ex-refund basis. Non-GAAP EPS of $1.56 ex-refund (up 14% YoY) and $1.62 including the $0.06 tariff-refund benefit.
Raised Full-Year Guidance
Updated fiscal year core revenue growth guide raised to 5.8%–6.0% (midpoint +65 bps vs prior guide). Full-year EPS guide increased to $6.18–$6.21 including refund impact (or $6.12–$6.15 ex-refund), implying ~10% EPS growth on an ex-refund basis at the midpoint.
Robust Cash Generation and Balance Sheet
Operating cash flow of $519M in Q3, capital expenditures $80M, free cash flow $439M (non-GAAP net income conversion ~96%). Returned capital via $78M share repurchases and $72M dividends; ended quarter with net leverage ~1.0x and completed $600M senior notes offering.
Pharma & Advanced Therapeutics Outperformance
Pharma end market grew 12% YoY; biotech grew double-digits. Advanced Therapeutics Division (specialty CDMO and BIOVECTRA) grew nearly 30% in Q3, with GLP-1 related sales up >70% YoY.
Product and Commercial Momentum
New product launches tracking ahead: 9500 Triple Quad ICP-MS funnel >$60M and exceeded ramp targets; 8890B/8860B GC orders in first 2 months >2x expectations; Altura column family shipments began with 28% quarter-over-quarter growth in new biopharma accounts adopting Altura.
China and Asia Acceleration
China revenue grew 9% (vs prior expectation of flat) with competitive wins (including 2 leading CXOs and a marquee local pharma enterprise service contract). Asia ex-China also grew 9% with robust pharma and CAM growth.
Ignite Operating System Benefits
Ignite-driven initiatives delivered ~200 basis points of strategic pricing in Q3 and contributed to manufacturing, supply-chain and commercial execution gains (order-to-shipment conversion improved, customer requested delivery performance reached a record 95%).
Instrument Replacement Cycle and Demand Signals
LC revenue grew low double-digits despite a mid-teens compare; GC revenue grew low single-digits against a high single-digit compare. Book-to-bill >1 for the 10th consecutive quarter, supporting near-term instrument demand and consumables/service pull-through.
Sustainability and External Recognition
Received multiple recognitions: TIME's World's Most Sustainable Companies, Newsweek's World's Greenest Companies, MSCI upgrade from AA to AAA, joined the UN Global Compact, and received My Green Lab 2025 Sustainable Lab Product Innovation Award for Infinity III LC.
MX:A Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed